much of the writing about the zyprexa documents has appeared in the new york times , but the times of london is now chiming in as well here 's a couple of choice cuts in one document dated october , , robert baker , a senior lilly clinical research physician , e mailed colleagues about a meeting of an academic advisory board he had attended in atlanta it had reinforced my impression that hyperglycemia remains quite a threat for olanzapine and may merit increasing even further medical attention and marketing focus on this topic dr baker added the board was quite impressed by the magnitude of weight gain on olanzapine and implications for glucose another internal document dated october , , described the risk of weight gain as a top threat to zyprexa link here background here , here , and here